Silo Pharma, Inc. (NASDAQ:SILO) Stock Short Interest Report for October

Silo Pharma, Inc. (NASDAQ:SILO) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 22,078 shares, a drop of 36.7% from the September 30th total of 34,870 shares. Currently, 1.4% of the company’s stock are short sold. Based on an average daily trading volume, of 156,498 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Silo Pharma stock. AdvisorShares Investments LLC raised its holdings in Silo Pharma, Inc. (NASDAQ:SILO) by 10.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 663,965 shares of the company’s stock after acquiring an additional 64,458 shares during the period. AdvisorShares Investments LLC owned 4.08% of Silo Pharma worth $239,000 at the end of the most recent reporting period. 5.58% of the stock is currently owned by institutional investors.

Silo Pharma Price Performance

Shares of NASDAQ SILO opened at $1.28 on Wednesday. Silo Pharma has a 52-week low of $1.10 and a 52-week high of $10.43. The business has a 50-day moving average price of $1.70 and a 200 day moving average price of $4.51.

Silo Pharma (NASDAQ:SILO) last announced its earnings results on Thursday, August 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.44). Silo Pharma had a negative return on equity of 81.75% and a negative net margin of 6,726.39%.

About Silo Pharma

Silo Pharma, Inc is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health.

Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia.